SCHEMBL2269839

SCHEMBL2269839

CC(C)(C)OC(=O)c1ccc(-c2ccccc2)cc1NC(=O)c1ccccc1F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 4/20 0.46
ACLY P53396 4/20 0.46
GAA P10253 1/20 0.46
MAPT P10636 3/20 0.45
ALDH1A1 P00352 2/20 0.45
POLB P06746 1/20 0.45
BLM P54132 1/20 0.45
RXFP1 Q9HBX9 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
HTT P42858 1/20 0.45
KMT2A Q03164 2/20 0.45
KDM4E B2RXH2 2/20 0.45
HDAC1 Q13547 2/20 0.44
WDR5 P61964 1/20 0.44
LMNA P02545 2/20 0.43
RAB9A P51151 2/20 0.43
NPSR1 Q6W5P4 1/20 0.43
MEN1 O00255 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
NPC1 O15118 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1316473 0.86 HDAC1 (0.51) ACLYKMT2AKDM4EHDAC1MEN1
SCHEMBL12117652 0.86 HDAC1 (0.48) ACLYALDH1A1KMT2AHDAC1MEN1
SCHEMBL2271206 0.85 MAPT (0.56) ACLYGAAMAPTPOLBKMT2A
SCHEMBL12117763 0.85 HDAC1 (0.47) ACLYALDH1A1KMT2AHDAC1WDR5
SCHEMBL1319007 0.85 HDAC1 (0.53) ACLYKDM4EHDAC1
SCHEMBL2276220 0.84 L3MBTL1 (0.55) L3MBTL1GAAALDH1A1RXFP1TDP1
SCHEMBL2273488 0.83 SUCNR1 (0.52) ACLYALDH1A1RXFP1KMT2AHDAC1
SCHEMBL4217591 0.83 ACLY (0.44) ACLYMAPTKDM4EHDAC1CYP1A2
SCHEMBL2271130 0.83 HSD17B10 (0.43) L3MBTL1ACLYGAAMAPTALDH1A1
SCHEMBL5145099 0.82 ACLY (0.61) L3MBTL1ACLYGAATDP1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101094829-B novel anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO.,LTD. (JP) 2012-02-08 CN disclosed
US-7999132-B2 Anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2011-08-16 US disclosed
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-09-24 US disclosed
CN-101094829-A Novel anthranilic acid derivative or salt thereof TOYAMA CHEMICAL CO LTD (JP) 2007-12-26 CN disclosed
EP-1820795-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2007-08-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090240052-A1 NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF MMP13, MMP26, MMP11 L3MBTL1 3822/4885ACLY 653/4885GAA 2590/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.